Immunological measurement of aspartate/alanine aminotransferase in predicting liver fibrosis and inflammation

키워드

참고문헌 (34)

1. Felig P, "The glucose-alanine cycle", Metabolism, 22, pp.179~207 (1973)
2. Daxboeck F, "Elevated serum alanine aminotransferase (ALT) levels in patients with serologically verified Mycoplasma pneumoniae pneumonia", Clin Microbiol Infect, 11, pp.507~510 (2005)
3. Dufour DR, "Diagnosis and monitoring of hepatic injury. I. Performance characteristics of laboratory tests", Clin Chem, 46, pp.2027~2049 (2000)
4. Kim HJ, "Abundance of immunologically active alanine aminotransferase in sera of liver cirrhosis and hepatocellular carcinoma patients", Clin Chem, 55, pp.1022~1025 (2009)
5. Kim WR, "Serum activity of alanine aminotransferase (ALT) as an indicator of health and disease", Hepatology, 47, pp.1363~1370 (2008)
6. Nyblom H, "High AST", ALT ratio may indicate advanced alcoholic liver disease rather than heavy drinking, 2004, pp.39, 336~339
7. Nyblom H, "The AST", ALT ratio as an indicator of cirrhosis in patients with PBC, 2006, pp.26, 840~845
8. Lo RC, "Histopathological evaluation of liver fibrosis and cirrhosis regression", Clin Mol Hepatol, 23, pp.302~307 (2017)
9. Glinghammar B, "Detection of the mitochondrial and catalytically active alanine aminotransferase in human tissues and plasma", Int J Mol Med, 23, pp.621~631 (2009)
10. Ford GC, "Three-dimensional structure of a pyridoxal-phosphate-dependent enzyme, mitochondrial aspartate aminotransferase", Proc Natl Acad Sci U S A, 77, pp.2559~2563 (1980)
11. Stankewicz MJ, "Mitochondrial glutamate aspartate transaminase. Differential action of thiol reagents with the supernatant enzyme", Biochemistry, 10, pp.2877~2884 (1971)
12. Watanabe T, "Comparative studies on the primary structure of soluble and mitochondrial glutamic oxaloacetic transaminase isozymes. I. Similar peptides isolated by cyanogen bromide cleavage", Biochem Biophys Res Commun, 43, pp.1310~1317 (1971)
13. Jeong SY, "Sandwich ELISA for measurement of cytosolic aspartate aminotransferase in sera from patients with liver diseases", Clin Chem, 49, pp.826~829 (2003)
14. Leonardi F, "Anticoagulation in cirrhosis:a new paradigm?", Clin Mol Hepatol, 23, pp.13~21 (2017)
15. Runyon BA, "Introduction to the revised American Association for the Study of Liver Diseases Practice Guideline management of adult patients with ascites due to cirrhosis 2012", Hepatology, 57, pp.1651~1653 (2013)
16. Burroughs AK, "Hepatic venous pressure gradient in 2010: optimal measurement is key", Hepatology, 51, pp.1894~1896 (2010)
17. Ozkurt H, "Diffusion weighted MRI for hepatic fibrosis : impact of b-value", Iran J Radiol, 11, pp.e3555~ (2014)
18. "J Hepatol", 2003, 382~386
19. Asselah T, "Improving performance of liver biopsy in fibrosis assessment", J Hepatol, 61, pp.193~195 (2014)
20. Klingenberg B, "Multivariate extensions of Mc-Nemar's test", Biometrics, 62, pp.921~928 (2006)
21. Groszmann RJ, "Beta-blockers to prevent gastroesophageal varices in patients with cirrhosis", N Engl J Med, 353, pp.2254~2261 (2005)
22. Ripoll C, "Hepatic venous pressure gradient predicts clinical decompensation in patients with compensated cirrhosis", Gastroenterology, 133, pp.481~488 (2007)
23. Kim MY, "Hepatic venous pressure gradient can predict the development of hepatocellular carcinoma and hyponatremia in decompensated alcoholic cirrhosis", Eur J Gastroenterol Hepatol, 21, pp.1241~1246 (2009)
24. Kumar M, "Hepatic venous pressure gradient as a predictor of fibrosis in chronic liver disease because of hepatitis B virus", Liver Int, 28, pp.690~698 (2008)
25. Garcia-Tsao G, "Now there are many(stages)where before there was one : In search of a pathophysiological classification of cirrhosis", Hepatology, 51, pp.1445~1449 (2010)
26. Suk KT, "Diagnostic accuracy of hepatic venous pressure gradient measurement in the prediction of stage 1 compensated liver cirrhosis in patients with chronic hepatitis B", Eur J Gastroenterol Hepatol, 25, pp.1170~1176 (2013)
27. Wong GL, "Development of a non-invasive algorithm with transient elastography(Fibroscan)and serum test formula for advanced liver fibrosis in chronic hepatitis B", Aliment Pharmacol Ther, 31, pp.1095~1103 (2010)
28. Gressner OA, "Biomarkers of liver fibrosis : clinical translation of molecular pathogenesis or based on liver-dependent malfunction tests", Clin Chim Acta, 381, pp.107~113 (2007)
29. Cowan ML, "Proteomic approaches in the search for biomarkers of liver fibrosis", Trends Mol Med, 16, pp.171~183 (2010)
30. Paradis V, "Glycomics : a new taste of cirrhosis marker", J Hepatol, 43, pp.913~914 (2005)
31. Baranova A, "The role of genomics and proteomics : technologies in studying non-alcoholic fatty liver disease", Clin Liver Dis, 11, pp.209~220 (2007)
32. Lee MH, "Comparison of surrogate serum markers and transient elastography (Fibroscan)for assessing cirrhosis in patients with chronic viral hepatitis", Dig Dis Sci, 55, pp.3552~3560 (2010)
33. Jae-Won Huh, "Alu-Derived Old World Monkeys Exonization Event and Experimental Validation of the LEPR Gene", Molecules and Cells, 30(3), pp.201~207 (2010), 한국분자세포생물학회
34. Rustogi R, "Accuracy of MR elastography and anatomic MR imaging features in the diagnosis of severe hepatic fibrosis and cirrhosis", J Magn Reson Imaging, 35, pp.1356~1364 (2012)

관련 논문AI추천